Biotechnology
Ortho Clinical Diagnostics' Quantitative COVID-19 IgG Antibody Test First to Receive FDA Emergency Use Authorization
- Ortho's new VITROS® Anti-SARS-CoV-2 IgG Quantitative Test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinicians and public health leaders a standard tool to measure antibody response to SARS-CoV-2 - Ortho is ...
2021-07-10 03:33
29847
ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody
* ABL503/TJ-L14B demonstrates stronger anti-tumor efficacy than anti-PD-L1 or anti-4-1BB monotherapy as well as a good safety profile * ABL503 currently in Phase 1 trial to evaluate the safety, tolerability, MTD PK and PD in patients with advanced or metastatic solid tumors SEONGNAM, South Ko...
2021-07-09 21:00
2898
Sequanta and Mission Bio announce strategic partnership
SHANGHAI, July 8, 2021 /PRNewswire/ -- Sequanta Technologies Co., Ltd. ("Sequanta") and Mission Bio. ("Mission Bio") are pleased to announce that they have entered into a strategic partnership, providing high-quality single-cell sequence services using Mission Bio's products to customers in mainl...
2021-07-09 15:44
1809
Vaniam Group LLC announces European and International expansion with addition of new global agency, Vaniam Group Global Ltd
Dr. Louise Verrall appointed to lead Vaniam Group Global Ltd as Head of Europe & International CHICAGO, July 9, 2021 /PRNewswire/ -- Vaniam Group LLC today announced the establishment of Vaniam Group Global Ltd, expanding the company's strategic healthcare communications network footprint intoEu...
2021-07-09 06:50
2006
Yushangmei seeks to establish partnership with a new target company
GUANGZHOU, China, July 8, 2021 /PRNewswire/ -- Guangzhou Yushangmei Health Management Co., Ltd. announced the termination of the partnership with the company headquartered inNevada, USA. Meanwhile, Yushangmei has sought to establish partnership with a new target company, specific details will be ...
2021-07-08 19:29
3120
Aleph Farms Completes $105 Million Series B Funding Round
REHOVOT, Israel, July 8, 2021 /PRNewswire/ -- Aleph Farms
2021-07-08 12:04
2626
BioShin Expands Senior Leadership Team: Sarah Lu Joins BioShin as Chief Medical Officer, Mary Ma Joins BioShin as Chief Commercial Officer
SHANGHAI, July 8, 2021 /PRNewswire/ -- BioShin Limited today announced the appointment of Dr.Zhihong (Sarah) Lu as Chief Medical Officer and Dr. Ma (Mary) Li as Chief Commercial Officer. Sarah will play a critical role in BioShin's clinical development of pipeline products inAsia-Pacific markets,...
2021-07-08 12:01
2194
Just 5 minutes: Game-changing PCR to complete nucleic acid amplification, Si-Gene Biotech help out against COVID 19
SHANGHAI, July 8, 2021 /PRNewswire/ -- As is known, nucleic acid detection is currently the "golden standard" of coronavirus detection and has the high sensitivity and specificity characteristics in early diagnosis. The most common method for detecting novel coronavirus-specific nucleic acid sequ...
2021-07-08 11:28
1887
CStone announces updated results for AYVAKIT(R) (avapritinib) in Chinese patients with advanced GIST at ESMO World Congress on Gastrointestinal Cancer 2021
* AYVAKIT has demonstrated significant anti-tumor activity in Chinese patients with PDGFRA D842V mutant gastrointestinal stromal tumor (GIST), and has also shown potential for the treatment of fourth-line GIST * AYVAKIT had a generally well-tolerated safety profile in Chinese patients with GI...
2021-07-08 08:05
3285
New Cancer Treatment For Australian Dogs With APVMA Approval Of Qbiotics' Stelfonta®
* STELFONTA® (tigilanol tiglate) is now approved by the Australian Pesticides and Veterinary Medicines Authority (APVMA) for the treatment of canine non-metastatic mast cell tumours (MCT). * APVMA approval follows marketing authorisation (registration) and launch of STELFONTA® in the major co...
2021-07-07 06:34
1729
LBB Specialties Enters Agreement with Leading Innovative Actives Manufacturer GREAF
NORWALK, Conn., July 7, 2021 /PRNewswire/ -- LBB Specialties (LBBS), a leader in North American specialty chemicals and ingredients distribution, announced it has entered a contractual agreement withGREAF, the global supplier of responsibly sourced, plant-derived novel active ingredients. The agr...
2021-07-07 01:45
1928
Immunogenicity Expert and FDA Alum Dr. Amy Rosenberg Joins EpiVax
PROVIDENCE, R.I., July 7, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce that Dr.Amy Rosenberg is leaving the FDA's Division of Therapeutic Proteins, CDER, which she led for over 20 years, to join EpiVax as Senior Director of Immunology and Protein Therapeutics. Dr. Rosenber...
2021-07-07 01:43
2207
Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis
* Both batoclimab 340 mg and 680 mg treatment groups demonstrated rapid, substantial and persistent clinical improvement over placebo * Favorable safety and tolerability profile with no serious adverse events (SAEs) and no adverse events (AEs) leading to discontinuation * Strong IgG reductio...
2021-07-06 21:06
17979
Bon Natural Life Limited Announces Land Acquisition to Construct Its Third Production Facility
XIAN, China, July 6, 2021 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solutions provider in the natural, health and personal care industries, today announced that they have received the certificate of a land use right for the future si...
2021-07-06 21:00
3968
Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD
ADELAIDE, Australia, July 6, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics or Company), a global, clinical stage biopharmaceutical company, is pleased to announce that it has initiated a Phase2b trial (the ATTUNE Study) to evaluate the tablet formulation of BNC210 in p...
2021-07-06 18:00
17011
Seegene announces partnership with Bio-Rad to develop diagnostic testing products for the U.S. Market
* Seegene announces partnership with Bio-Rad for the development and commercialization of infectious disease molecular diagnostic products * Diagnostic tests designed for the pandemic and the post-pandemic era with high multiplex technology * A significant step forward for Seegene in expandi...
2021-07-06 18:00
1848
PolyU develops highly sensitive, microscopic optical fibre sensors with pioneering biomedical monitoring capability
HONG KONG, July 6, 2021 /PRNewswire/ -- The Hong Kong Polytechnic University (PolyU) has made a breakthrough development in optical fibre sensors, making the advanced railway safety monitoring technologies available for medical surveillance inside the human body. The research team led by Profess...
2021-07-06 17:06
1428
Clover Biopharmaceuticals Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2/3 Clinical Trial for its COVID-19 Vaccine Candidate
* SPECTRA enrolled over 29,000 adult and elderly participants across four continents achieving high ethnic diversity and robust dataset of circulating strains * Release of vaccine efficacy data anticipated in Q3 2021 and will include sequencing data of SARS-CoV-2 variants of concern and varia...
2021-07-06 14:00
2509
Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF)
SHANGHAI and HONG KONG, July 6, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
2021-07-06 08:00
3391
South-Korean biotech Y-Biologics and French mid-pharma Pierre Fabre enter into a worldwide exclusive license agreement in the highly innovative field of immuno-oncology
DAEJEON, South Korea and CASTRES, France, July 6, 2021 /PRNewswire/ -- The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have entered into a license agreement granting worldwide exclusive rights toPierre Fabre to develop and commercialize a family of hum...
2021-07-06 07:00
2777
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7433
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
6834
